HUE050713T2 - Módszerek az ALFA-4 integrin aktivitás eltéréseinek meghatározásához, a sVCAM ÉS/VAGY sMAdCAM szintek egymáshoz viszonyításával - Google Patents
Módszerek az ALFA-4 integrin aktivitás eltéréseinek meghatározásához, a sVCAM ÉS/VAGY sMAdCAM szintek egymáshoz viszonyításávalInfo
- Publication number
- HUE050713T2 HUE050713T2 HUE17192860A HUE17192860A HUE050713T2 HU E050713 T2 HUE050713 T2 HU E050713T2 HU E17192860 A HUE17192860 A HU E17192860A HU E17192860 A HUE17192860 A HU E17192860A HU E050713 T2 HUE050713 T2 HU E050713T2
- Authority
- HU
- Hungary
- Prior art keywords
- differences
- svcam
- alpha
- methods
- correlating
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40635810P | 2010-10-25 | 2010-10-25 | |
| US40636510P | 2010-10-25 | 2010-10-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE050713T2 true HUE050713T2 (hu) | 2020-12-28 |
Family
ID=46024768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17192860A HUE050713T2 (hu) | 2010-10-25 | 2011-10-24 | Módszerek az ALFA-4 integrin aktivitás eltéréseinek meghatározásához, a sVCAM ÉS/VAGY sMAdCAM szintek egymáshoz viszonyításával |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20130337470A1 (hu) |
| EP (3) | EP3722808B1 (hu) |
| JP (2) | JP5847188B2 (hu) |
| AU (4) | AU2011323820A1 (hu) |
| CA (1) | CA2816016A1 (hu) |
| CY (1) | CY1123060T1 (hu) |
| DK (1) | DK3326645T3 (hu) |
| ES (2) | ES2800066T3 (hu) |
| HK (1) | HK1256157A1 (hu) |
| HR (1) | HRP20200920T1 (hu) |
| HU (1) | HUE050713T2 (hu) |
| LT (1) | LT3326645T (hu) |
| PL (1) | PL3326645T3 (hu) |
| PT (1) | PT3326645T (hu) |
| RS (1) | RS60565B1 (hu) |
| SI (1) | SI3326645T1 (hu) |
| WO (1) | WO2012061074A1 (hu) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3326645T3 (pl) | 2010-10-25 | 2020-09-21 | Biogen Ma Inc. | Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM |
| JP2018504584A (ja) * | 2014-12-02 | 2018-02-15 | ネステク ソシエテ アノニム | 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5338689A (en) | 1987-08-24 | 1994-08-16 | Stiftung Fur Diagnostische Forschung | Method and card for detecting antigens and/or antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5730978A (en) | 1989-09-01 | 1998-03-24 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with α4β1-specific antibodies |
| US7238668B1 (en) | 1989-09-01 | 2007-07-03 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof |
| US5260210A (en) | 1989-09-27 | 1993-11-09 | Rubin Lee L | Blood-brain barrier model |
| US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5224539A (en) | 1991-06-14 | 1993-07-06 | Coen Company, Inc. | Cooling system for air heaters and the like |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| US5871734A (en) | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
| US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AU688751B2 (en) | 1993-01-12 | 1998-03-19 | Biogen Idec Ma Inc. | Recombinant anti-VLA4 antibody molecules |
| NZ262615A (en) | 1993-02-09 | 1996-02-27 | Biogen Inc | Treating insulin dependent diabetes (type i) with anti vla4 (very late antigen) antibodies |
| US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| GB9406974D0 (en) | 1994-04-08 | 1994-06-01 | Pharmaceutical Proteins Ltd | Transgenic production |
| BE1008817A6 (fr) | 1994-10-28 | 1996-08-06 | Univ Bruxelles | Procede d'obtention d'adn bicatenaire membranaire humain, produit obtenu par ce procede et trousse de diagnostic le contenant. |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| GB9712818D0 (en) | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
| DE19647381A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| PL323130A1 (en) | 1996-11-15 | 1998-05-25 | Hoechst Ag | Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such |
| US5965356A (en) | 1997-01-31 | 1999-10-12 | University Of Maryland, Baltimore | Herpes simplex virus type specific seroassay |
| US6489300B1 (en) * | 1997-07-31 | 2002-12-03 | Eugene D. Thorsett | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| DE19741235A1 (de) | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19741873A1 (de) | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
| EP1078006B1 (en) * | 1998-05-13 | 2009-03-04 | Genentech, Inc. | Diagnosis and treatment of hepatic disorders |
| DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19922462A1 (de) | 1999-05-17 | 2000-11-23 | Aventis Pharma Gmbh | Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| US6756378B2 (en) | 1999-06-30 | 2004-06-29 | Pharmacopeia Drug Discovery, Inc. | VLA-4 inhibitor compounds |
| NZ518886A (en) | 1999-12-28 | 2004-02-27 | Pfizer Prod Inc | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
| US7160541B2 (en) * | 2000-09-01 | 2007-01-09 | The Center For Blood Research, Inc. | Modified polypeptides stabilized in a desired conformation and methods for producing same |
| DE10111877A1 (de) | 2001-03-10 | 2002-09-12 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE10137595A1 (de) | 2001-08-01 | 2003-02-13 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung |
| MY157727A (en) | 2002-02-25 | 2016-07-15 | Biogen Idec Inc | Administration of agents for the treatment of inflamation |
| EP1592387A4 (en) | 2003-01-24 | 2009-05-06 | Elan Pharm Inc | COMPOSITION AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS |
| SI3417875T1 (sl) | 2003-02-10 | 2021-01-29 | Biogen Ma Inc. | Formulacija imunoglobulina in metode za njegovo pripravo |
| ZA200606557B (en) | 2004-02-06 | 2008-02-27 | Elan Pharm Inc | Methods and compositions for treating tumors and metastatic disease |
| MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
| AU2005231467A1 (en) | 2004-04-01 | 2005-10-20 | Elan Pharmaceuticals, Inc. | Steroid sparing agents and methods of using same |
| US7196112B2 (en) | 2004-07-16 | 2007-03-27 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
| NZ560844A (en) | 2005-03-08 | 2008-08-29 | Pharmacia & Upjohn Co Llc | Anti-MAdCAM antibody compositions |
| EP1872136B9 (en) * | 2005-04-04 | 2023-02-08 | Biogen MA Inc. | Methods and products for evaluating an immune response to a therapeutic protein |
| LT2676967T (lt) | 2006-02-28 | 2019-09-10 | Biogen Ma Inc. | Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu |
| BRPI0708392A2 (pt) | 2006-03-03 | 2011-05-24 | Elan Pharm Inc | métodos de tratamento de um paciente com uma doença inflamatória ou autoimune com natalizumab e de uso de natalizumab para tratar um paciente com uma doença inflamatória ou autoimune |
| JP2011506322A (ja) | 2007-12-07 | 2011-03-03 | エラン ファーマシューティカルズ，インコーポレイテッド | 液性腫瘍を治療するための方法および組成物 |
| BRPI0908665A2 (pt) * | 2008-05-16 | 2020-08-18 | Genentech Inc | método para a determinação da eficácia de um antagonista de integrina beta7 para o tratamento de um distúrbio inflamatório gastrointestinal, método de predição da responsividade de um paciente, método para a determinaçao da dosagem de um antagonista de integrina beta7, método para determinaçao do regime terapêutico de um antagonista de integrina beta7, método para predição de prognóstico de uma doença inflamatória intestinal, método de elaboração de um tratamento e método de identificação de uma população de linfócitos |
| WO2009141786A2 (en) | 2008-05-21 | 2009-11-26 | Piramal Life Sciences Limited | Anti-inflammatory compounds |
| WO2010053316A2 (en) | 2008-11-06 | 2010-05-14 | Snu R&Db Foundation | New use of sixth immunoglobulin-like domain of vcam-1 |
| NZ577731A (en) * | 2009-06-16 | 2010-08-27 | Innate Therapeutics Ltd | Compositions and methods for treatment of multiple sclerosis |
| AU2011245140A1 (en) * | 2010-04-30 | 2012-12-20 | Elan Pharmaceuticals, Inc. | Selective integrin inhibitors |
| PL3326645T3 (pl) | 2010-10-25 | 2020-09-21 | Biogen Ma Inc. | Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM |
-
2011
- 2011-10-24 PL PL17192860T patent/PL3326645T3/pl unknown
- 2011-10-24 HU HUE17192860A patent/HUE050713T2/hu unknown
- 2011-10-24 US US13/881,520 patent/US20130337470A1/en not_active Abandoned
- 2011-10-24 SI SI201131889T patent/SI3326645T1/sl unknown
- 2011-10-24 EP EP20162844.3A patent/EP3722808B1/en active Active
- 2011-10-24 EP EP11838481.7A patent/EP2632492B1/en active Active
- 2011-10-24 ES ES17192860T patent/ES2800066T3/es active Active
- 2011-10-24 CA CA2816016A patent/CA2816016A1/en active Pending
- 2011-10-24 DK DK17192860.9T patent/DK3326645T3/da active
- 2011-10-24 ES ES11838481.7T patent/ES2654820T3/es active Active
- 2011-10-24 JP JP2013536701A patent/JP5847188B2/ja active Active
- 2011-10-24 LT LTEP17192860.9T patent/LT3326645T/lt unknown
- 2011-10-24 PT PT171928609T patent/PT3326645T/pt unknown
- 2011-10-24 EP EP17192860.9A patent/EP3326645B1/en active Active
- 2011-10-24 RS RS20200712A patent/RS60565B1/sr unknown
- 2011-10-24 AU AU2011323820A patent/AU2011323820A1/en not_active Abandoned
- 2011-10-24 WO PCT/US2011/057519 patent/WO2012061074A1/en active Application Filing
-
2014
- 2014-02-19 HK HK18115240.6A patent/HK1256157A1/zh unknown
-
2015
- 2015-08-27 JP JP2015167690A patent/JP2015215363A/ja not_active Withdrawn
-
2016
- 2016-04-18 US US15/131,804 patent/US11079393B2/en active Active
-
2017
- 2017-03-10 AU AU2017201658A patent/AU2017201658B2/en active Active
-
2019
- 2019-06-12 AU AU2019204089A patent/AU2019204089A1/en not_active Abandoned
-
2020
- 2020-06-08 HR HRP20200920TT patent/HRP20200920T1/hr unknown
- 2020-06-17 CY CY20201100555T patent/CY1123060T1/el unknown
-
2021
- 2021-08-03 US US17/393,267 patent/US20220206012A1/en active Pending
- 2021-08-05 AU AU2021212059A patent/AU2021212059A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11079393B2 (en) | 2021-08-03 |
| AU2017201658B2 (en) | 2019-03-21 |
| EP3326645A1 (en) | 2018-05-30 |
| EP2632492A1 (en) | 2013-09-04 |
| CA2816016A1 (en) | 2012-05-10 |
| JP2015215363A (ja) | 2015-12-03 |
| WO2012061074A1 (en) | 2012-05-10 |
| EP2632492A4 (en) | 2014-04-02 |
| EP3722808A1 (en) | 2020-10-14 |
| AU2021212059A1 (en) | 2021-08-26 |
| PL3326645T3 (pl) | 2020-09-21 |
| AU2011323820A1 (en) | 2013-05-23 |
| EP3722808B1 (en) | 2024-09-11 |
| US20220206012A1 (en) | 2022-06-30 |
| ES2654820T3 (es) | 2018-02-15 |
| US20160291035A1 (en) | 2016-10-06 |
| EP3326645B1 (en) | 2020-03-18 |
| CY1123060T1 (el) | 2021-10-29 |
| RS60565B1 (sr) | 2020-08-31 |
| AU2019204089A1 (en) | 2019-07-04 |
| ES2800066T3 (es) | 2020-12-23 |
| JP5847188B2 (ja) | 2016-01-20 |
| AU2017201658A1 (en) | 2017-03-30 |
| HK1256157A1 (zh) | 2019-09-13 |
| SI3326645T1 (sl) | 2020-09-30 |
| JP2014500950A (ja) | 2014-01-16 |
| US20130337470A1 (en) | 2013-12-19 |
| LT3326645T (lt) | 2020-08-10 |
| EP2632492B1 (en) | 2017-10-04 |
| HRP20200920T1 (hr) | 2020-10-30 |
| PT3326645T (pt) | 2020-06-23 |
| DK3326645T3 (da) | 2020-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1232292A1 (zh) | 樣品使用最大化的系統和方法 | |
| EP2700061A4 (en) | SYSTEMS AND METHOD FOR ANALYZING ENERGY CONSUMPTION | |
| HK1206065A1 (en) | Compositions and methods for analyte detection | |
| HK1193471A1 (zh) | 識別和測量網狀細胞 | |
| GB2516204B (en) | Multi-cue object detection and analysis | |
| EP2673631A4 (en) | METHOD AND SYSTEMS FOR DETERMINING THE PRESENCE OR QUANTITY OF TESTOSTERONE IN A SAMPLE | |
| EP2456361A4 (en) | SYSTEMS FOR CONTINUOUS ANALYTING MEASUREMENT AND SYSTEMS AND METHOD FOR THE IMPLEMENTATION THEREOF | |
| EP2683810A4 (en) | METHOD AND SYSTEM FOR CELL DETECTION AND ANALYSIS | |
| SG11201401016YA (en) | Web inspection calibration system and related methods | |
| SG11201401956XA (en) | Undifferentiated cell detection method and complex carbohydrate detection method | |
| EP2553657A4 (en) | METHODS AND APPARATUS FOR FACIAL DETECTION | |
| EP2703494A4 (en) | CELL ANALYSIS METHOD, DEVICE AND PROGRAM | |
| EP2584964A4 (en) | SYSTEMS AND METHODS FOR MONITORING SUBSTANCE TO BE ANALYZED | |
| EP2788794A4 (en) | PERMEABILITY PREDICTION SYSTEMS AND METHODS INVOLVING QUADRATIC DISCRIMINANT ANALYSIS | |
| ZA201208522B (en) | Methods for measuring enzyme activity useful in determining cell viability in non-purified sapmles | |
| IL222752A0 (en) | Acoustic methods and systems for detecting terahertz radioation | |
| EP2533049A4 (en) | PRETREATMENT SOLUTION FOR IMMUNOHISTOCHEMICAL COLORING AND CONDENSED SOLUTION THEREOF | |
| EP2726813A4 (en) | SURFACE MEASURING SYSTEM AND METHOD | |
| EP2553115A4 (en) | METHODS OF CULTURE AND ANALYSIS OF CELLS | |
| EP2650875A4 (en) | PITCH ORDER DETERMINATION DEVICE, TRACK ORDER DETERMINATION METHOD, AND TRACK ORDER DETERMINATION PROGRAM | |
| EP2640407A4 (en) | PROCESS FOR INCREASING THE EXPRESSION AND ACTIVITY OF NEPRILYSIN | |
| EP2576809A4 (en) | MEASURE A YEAST CONCENTRATION AND LIFE CAPABILITY | |
| EP2612257A4 (en) | SYSTEMS AND METHODS FOR ANALYZING DOCUMENTS | |
| GB201207583D0 (en) | Electrochemical detection method and related aspects | |
| EP2790033A4 (en) | GAP PROCESS AND DEVICE, AND MOLDING DEVICE WITH INSTALLED GAP MEASUREMENT DEVICE |